Table 6.
a) Hemodilution assessment through the ALLgorithMM. Samples are stratified into three main groups, defined as hemodiluted (HD), mildly hemodiluted (mHD) and non-hemodiluted (nonHD) by the result of the ALLgorithMM application. b) The impact of hemodilution on MRD evaluation. For each category, the number and the relative percentage are referred to hemodiluted or mildly hemodiluted samples, enlightening the potential impact of hemodilution on the minimal residual disease (MRD) measurement results, as assessed by flow cytometry (FC) or by molecular (mol, via NGS) approaches.
| a) | HD | mHD | nonHD | ||
|---|---|---|---|---|---|
| ALL | 17/69 (25%) | 8/69 (12%) | 44/69 (63%) | ||
| MM | 33/150 (22%) | 46/150 (31%) | 71/150 (47%) | ||
| CAR-T* | 2/14 (14%) | 4/14 (29%) | 8/14 (57%) | ||
| Tot | 52/233 (22%) | 58/233 (25%) | 123/233 (53%) | ||
| b) | FC MRD neg | FC MRD pos | mol MRD neg | mol MRD pos | mol MRD pnq |
| ALL | 25 (8; 32%) | 23 (9; 39%) | 26 (6; 23%) | 13 (7; 54%) | 7 (2; 29%) |
| MM | na** | na | 38 (27; 71%) | 16 (4; 25%) | 32 (18; 56%) |
| Tot | 25 (8; 32%) | 23 (9; 39%) | 64 (33; 52%) | 29 (11; 38%) | 39 (20; 51%) |
*CAR-T is referred only to MM patients underwent to CAR-T therapy in general (i.e., anti-BCMA CAR-T) after at least 56 days from the infusion; **Not applicable (na), as our center does not perform MRD evaluations by flow cytometry for MM patients.